THE DEAL, AT A GLANCE
From the announcementKhartis Therapeutics
01Who is involvedBacked by Forge Life Science Partners, Longwood Fund, Alexandria Venture Investments, Foresite CapitalFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02What happenedKhartis Therapeutics raised $50M Series B, announced 2026-08-13From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03Why it mattersKhartis Therapeutics' Series B positions the company to advance an oral small molecule immunology pipeline with backing from a life sciences investor syndicate.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Khartis Therapeutics · Financing Record
Explore source-linked visual explanations for Khartis Therapeutics. Unsupported claims are withheld while source review continues.
Record 10226 · Recorded date: 2026-08-13
What it does
Unsupported business claims are withheld pending source review. Explore the linked records for available evidence.
Explore company records →